Vesalius Biocapital has held a final close for its third life sciences venture capital fund at €120 million. Vesalius Biocapital III will invest in later stage companies across Europe.
The fund’s investor base includes new and existing investors from Europe, the Americas and MENA, including the European Investment Fund, which committed €30 million.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: